Paired serum and plasma samples from subjects were analyzed to determine if there was a difference in the insulin content of serum and plasma. Although there was no difference in the serum and plasma insulin concentrations in the samples as a group, there were differences in the serum and plasma insulin concentrations in individual subjects. Recovery of radioimmunoassayable insulin from clotted or heparinized blood is less than the recovery from serum or plasma, apparently because of association of insulin with the blood cells. Serum and plasma insulin concentrations are not altered when blood stands at room temperature for as long as 4 h. Storage at -20 #{176}C for 28 months results in similar decreases in the insulin content of serum (74%) and plasma (76%). We Conclude that one should Consistently use either serum or plasma for insulin measurements in individual patients.
Additional Keyphrases:
HGH compared #{149} stability of insulin in serum, plasma #{149} inter-individual differences #{149} sample validity Both serum and plasma are thought to be suitable for the radioimmunoassay of circulating insulin.
Henderson
(1) examined 42 pairs of serum and plasma samples and reported that the concentration of insulin in heparinized-plasma is much higher than that found in serum. In a recent study we (2) found no significant differences in the insulin concentrations in 114 pairs of heparin-plasma and serum samples. Our findings would result if there is in fact no difference in the insulin concentrations in serum and plasma. Such results might also occur if there are differences in serum and plasma insulin concentrations in individual patients, but the number of subjects with higher serum values is similar to the number with higher plasma values. Here, we attempt to answer this question and to determine if serum or plasma is preferable for the radioimmunoassay of insulin.
Materials and Methods

Procedure
To evaluate the effect of heparin on insulin measurements, duplicate blood samples were obtained from outpatients having blood drawn for oral glucose-tolerance tests, for chemical assays of blood obtained after overnight fasting, and postprandial determinations of glucose in serum. The patients included both diabetic and nondiabetic individuals, but none had received exogenous insulin therapy. After 4 ml of blood was collected in a plain "Vacutamer" tube, 2 ml was immediately transferred to a Vacutainer tube containing 50 mt. units of sodium heparin. Both tubes were kept in an ice bath for 2 to 3 h, then centrifuged, and the plasma or serum was removed and either immediately assayed for insulin or growth hormone or stored at -15 #{176}C for a month or less and then assayed for insulin or growth hormone. One group of insulin samples was stored at -20 #{176}C for 18 months and another group for 28 months after the initial assay, and both groups were then re-analyzed for insulin content.
To determine insulin recovery from serum and plasma, we collected 10 ml of blood in a plain "Vacutainer" (Becton-Dickinson, Rutherford, N. J. 07070) tube. An aliquot of blood was immediately placed in a heparin-Vacutainer tube to achieve a heparin concentration of 25 mt. units/ml. After centrifuging the tubes, two 1-ml aliquots of plasma and two 1-ml aliquots of serum were removed. Fifty microunits of human insulin in 50 121of a 10 g/liter solution of BSA2 was added to one serum and one plasma aliquot, while the other serum and plasma aliquots only received 50 121of the BSA. The insulin content of the samples with and without the added insulin was assayed, and the percentage recovery of added insulin calculated.
For determining insulin recovery from whole blood, 10 ml of blood was collected in a plain Vacutamer tube. The blood was immediately divided into four aliquots of 2 ml each. heparin. Fifty 1 of a solution of human insulin (1000 microunits/ml) was added to one of the heparinized tubes, 50 121of 1% BSA to the other. Two of the aliquots were placed in plain tubes. Fifty microliters of human insulin standard (1000 microunits/ml) was added to one of the two plain tubes, 50 121of BSA (10 g/liter) to the other. The tubes were kept in an ice bath for 2 to 3 h and then centrifuged.
After determining the packed cell volume (hematocrit) of the heparinized blood samples, we removed the plasma or serum from the tubes and assayed for insulin. We assumed that the added insulin was distributed in the plasma or serum and was excluded from the erythrocytes.
The percentage of added insulin recovered from heparinized and clotted blood was then calculated.
In our studies involving the recovery of 1251-labeled insulin from blood, the insulin tracer was purified of damaged insulin within the 48 h before the study. We used the following procedure (3):
(10 pCi) is incubated with 100 pl of undiluted normal guinea pig serum and 100 pl of bromphenol blue-stained BSA (10 g/liter) for 18 to 20 h at 4 #{176}C (total volume, 0.25 ml). The contents are then placed on a 15 x 1 cm column containing "Sephadex G-75" (Pharmacia Labs. Inc., Piscataway, N. J. 08854) and eluted at a rate of 3-4 mI/h, with phosphate buffer (25 mmol/ liter) of the composition described in "Methods"; 0.5-ml fractions are collected. The first radioactive peak, which appears with the dye marker, is "damaged" insulin, and is discarded. The second radioactive peak contains the purified insulin, and only 2% of the "damaged" insulin remains in this preparation.
Methods
Insulin was measured by a double-antibody modification (2, 3) of a procedure in which '251-labeled pork insulin is used (3). The sensitivity of this assay in plasma or serum is 2.5 microunits of insulin per milliliter.
Within one assay, this method has a 10% coefficient of variation for plasma samples containing 10 or more microunits of insulin per milliliter and a 27% coefficient of variation for samples containing 2 to 10 microunits of insulin per milliliter. Serum and plasma human growth hormone (HGH) were assayed by using '251-labeled HGH as tracer and HGH as standards (4). The sensitivity of this assay for growth hormone in plasma or serum is 0.25 ng/ml.
All reagents were dissolved in phosphate buffer (25 mmol/liter, pH 7.4, containing, per liter, 9 g of NaC1, 0.1 g of thiomerosal, and 2 g of BSA 
Results
Insulin Concentrations in Serum and Plasma of Individual Patients
We previously reported (2) that there is no significant difference in insulin concentrations in serum and heparin-plasma, as measured in paired samples obtained from 114 subjects. To determine if there are differences in serum and plasma insulin concentrations in individual patients, we selected a series of six patients from the 114 patients and eight replicate determinations of insulin were made on both serum and plasma. We purposely selected samples for replicate analysis that appeared to have discordant values for serum and plasma insulin concentrations. The possible statistical significance between the serum and plasma insulin concentrations was estimated by Student's t test. Table 1 shows that insulin in some subject's serum was higher than in their plasma (Pts. 1 and 2), in some subjects serum and plasma insulin were the same (Pts. 3 and 4), and in other subjects plasma insulin was higher than serum (Pts. 5 and 6). To determine if such differences persist during repeat sampling, we made replicate determinations on serum and plasma from individual patients at the various time intervals of an oral glucose tolerance test (Table 2) . If the serum insulin concentration is higher than the plasma insulin concentration, it remains higher or is identical to the plasma insulin at the different sampling times. Plasma insulin never exceeded serum insulin.
To determine if there is day-to-day consistency, we drew blood samples from two volunteers every other day for 10 days (five samples from each volunteer). In one, there was no difference in serum and plasma insulin from day to day, while the other's plasma insulin content exceeded his serum insulin content on four of the five days.
To determine if the in vitro addition of heparin alters insulin measurements, we added heparin to the serum of subjects who had plasma insulin concentrations greater than their serum insulin concentrations.
Although the heparin content of the serum was now identical to the heparin content of plasma, this did not increase the apparent concentration of insulin in the "serum." Evidently the differences in serum and plasma insulin are not due simply to added heparin. HGH was measured in 98 of the 114 specimens that were previously analyzed for insulin. The mean serum HGH concentration of the group was 3.1 ± 0.41 (stand. error) ng/ml, the plasma HGH was 3.0 ± 0.42 ng/ml. Concentrations in serum and plasma did not differ, even by the sensitive paired t test.
Human Growth Hormone (HG H) Concentrations in Serum and Plasma
To determine if there are differences in serum and plasma HGH concentrations in individual patients, we selected a series of eight patients from the 98 patients, and made eight replicate determinations of insulin in both serum and plasma. Although we tried to select samples that had discordant values for serum and plasma HGH content, such discordant samples were infrequent when compared to the frequency of samples with discordant serum and plasma insulin concentrations. Table 3 shows the results of the replicate studies. In contrast to insulin concentrations in serum and plasma, the values for HGH content of serum and plasma were not significantly different for any of the serum-plasma pairs.
Recovery Studies
Recovery of radioimmunoassayable insulin from serum and plasma. Twenty-five additional pairs of serum and heparin-plasma samples were obtained, and the percentage recovery of added nonradioactive insulin was determined as described in "Methods." The initial insulin content of the sera was 22 ± 5.4 (SE) microunits/ml; that of the plasma samples was 21 ± 5.5 microunits/ml. Serum insulin and plasma insulin concentrations correlated significantly (r = 0.99, P <.01) in individual patients.
Of the added insulin, 90 ± 4.4% was recovered from sera, 86 ± 2.7% from plasma samples. There was no significant difference in the initial insulin content of the serum (17 ± 3.1 rnicrounits/ml) and the plasma (17 ± 3.1 microunits/ml) (mean ± stand, error). There was a significant correlation between the serum insulin and the plasma insulin concentrations in individual subjects (r = 0.9837, P <0.01). Considered as a group, there was no significant difference between the insulin recovery from clotted blood [81 ± 5.4% (SE)] and the insulin recovery from heparinized blood (71 ± 6.5%). Recovery of insulin from the clotted and heparinized blood samples of individual subjects were uncorrelated (r = 0). The insulin recovery from clotted or heparinized blood was lower and more variable than the insulin recovery from either serum or plasma described in the preceding section.
Distribution of [1251]lnsulin in Clotted and Heparinized Blood
The distribution of 25I-labeled insulin in clotted and heparinized blood was evaluated, to ascertain if the insulin recovery from blood was less than the insulin recovery from serum or plasma because insulin is bound to erythrocytes. Blood samples obtained from two volunteers were drawn into plain Vacutainer tubes. Half of each blood specimen was placed in a tube containing adequate heparin to achieve a blood heparin concentration of 25 mt. units/ml. One milliliter of plain blood and 1 ml of heparinized blood were added to tubes containing either 50 pl of phosphate buffer alone or 50 pl of phosphate buffer containing 10 milliunits of nonradioactive pork insulin. After the contents of the four tubes were mixed, 25 l of '25I-labeled pork insulin (3 microunits) was added to all of the tubes. The specific activity of the [1251]insulin used was about 160 mCi of 1251 per milligram of insulin. After standing in an ice bath for 2 h, the blood was centrifuged at 8000 X g at 2 #{176}C for 20 mm. The hematocrit of each sample was deter- mined and this measurement used to estimate the serum or plasma distribution space of the blood samples. When
[125I]insulin was added to a given volume of serum, plasma, or water, and a 50-al aliquot counted, the count rate was identical in the three media, indicating a 100% "recovery" of radioactive insulin in serum or plasma. However when a 50-l aliquot of serum (from clotted blood) or plasma (from heparinized blood) was counted and the count rate compared to that predicted if the insulin were uniformly distributed in the serum or plasma (based on the packed cell volume),
an average of only 85% of the predicted 1251 counts was present in the serum or plasma.
After the plasma was carefully aspirated from the packed cells, the per cent of the added ['251]insulin associated with the packed cell fraction was determined (Table  4) . In subject one, 16.7% of the [1251]insulin was associated in the absence of nonradioactive insulin and 15.5% in the presence of nonradioactive insulin.
The corresponding figures for subject two were 17.7% and 10.3%.
The packed cells were washed with 3 ml of physiological saline (9 g of NaC1 per liter) at 3 #{176}C, the cells centrifuged at 8000 X g, the supernatant saline was aspirated off, and the [125I]insulin associated with the cells determined. Table 4 indicates that although the counts associated with the cells decreased with successive washes, the [1251]insulin associated with the packed cells was always less in the groups in which nonradioactive insulin had also been added. After the cells had been washed again with physiological saline they were hemolyzed by use of an NaCl solution (3 g/liter) at 2 #{176}C. The stromal pellet was centrifuged (10 000 X g), the supernate aspirated, and the radioactivity assocated with the pellet determined.
Of the radioactivity associated with the packed cells, 25 to 50% remained associated with the erythrocyte stroma. This series of studies shows that a significant amount of [1281] insulin is associated with the packed cells, and that this association can be partially blocked by nonradioactive insulin.
Stability of Insulin in Serum and Plasma
On occasion there may be a delay in centrifuging blood samples in a laboratory. Blood was drawn from two volunteers to determine if the stability of insulin in clotted blood differs from its stability in heparinized
blood. An aliquot from each was placed in a heparinized tube to achieve a final heparin concentration of 25 mt. units/mi. The heparinized and nonheparinized blood was placed in tubes that were left at room temperature (25 #{176}C) for 0, 1, 2, 3, or 4 h. The tubes were then centrifuged at 6000 X g, the serum and plasma removed, and their insulin content determined by radioimmunoassay. Table  5 shows that the insulin value was stable in both serum and plasma during the 4-h observation.
To determine if insulin is more stable under storage conditions in serum or plasma, we assayed sam- alhree microunits of l'25llinsulin with specific activity 160 mCi/mg of insulin.
'Cold" insulin is 10000 microunits of nonradioactive pork insulin per blood tube. 0 Serum was obtained from clotted blood, and plasma was obtained from heparinized blood (25 mt. units/mI). The blood stood at 25 #{176}C for the specified number of hours before centrifugation. pairs were studied at 18 months and 24 pairs at 28 months. There were no significant differences in the insulin concentration of serum and plasma during initial or final analysis.
ples for insulin content that had been assayed, stored at -20 #{176}C for 18 months, thawed, and their insulin content again determined. Table 6 shows that the initialinsulin concentration of the serum and plasma samples were similar; the final insulin concentrations of the serum and plasma samples were also similar.There was a 59 ± 5.0% (SE) decrease in the insulinconcentration of the serum, a 57 ± 6.9% decrease in the insulin.levelof the plasma. There was a significant correlation (r = 0.49, P < .05) in the decrease in insulin content in paired serum and plasma samples. A second group of samples was stored at -20 #{176}C for 28 months and then reanalyzed for insulin. Table 6 shows that the initial
